Trials / Completed
CompletedNCT04406649
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 482 (actual)
- Sponsor
- Satsuma Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
Detailed description
The ASCEND trial is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dihydroergotamine | Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate. |
Timeline
- Start date
- 2020-09-14
- Primary completion
- 2023-01-16
- Completion
- 2023-01-16
- First posted
- 2020-05-28
- Last updated
- 2023-07-03
- Results posted
- 2023-07-03
Locations
44 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04406649. Inclusion in this directory is not an endorsement.